| Judith Handjinicolaou, | |
|
3301 New Mexico Ave Nw, Suite 210, Washington, DC 20016-3622 | |
| (202) 363-9600 | |
| (202) 363-9601 |
| Full Name | Judith Handjinicolaou |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 3301 New Mexico Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114902855 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Judith Handjinicolaou, 3301 New Mexico Ave Nw, Suite 210, Washington, DC 20016-3622 Ph: (202) 363-9600 | Judith Handjinicolaou, 3301 New Mexico Ave Nw, Suite 210, Washington, DC 20016-3622 Ph: (202) 363-9600 |
News Archive
Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI which can lead to possible earlier diagnosis and treatment, according to a new study by researchers from Ohio State University in Columbus, and Columbia University in New York.
The National Institutes of Health has awarded two five-year grants to Wake Forest Baptist Medical Center worth more than $5 million to prospectively study the effects of a genetic variation in organ donors that appears to contribute to survival of kidneys after transplantation.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States sclerotherapy market will experience rapid procedural growth stemming from favorable patient demographics and increased patient demand. Polidocanol, a sclerosing agent used to chemically treat varicose and spider veins, received FDA approval in 2010 and is expected to show significant growth in the US.
The wide range of manifestations of COVID-19 has continued to baffle investigators. Now, a new study published on the preprint server medRxiv in June 2020 shows that blood proteins in COVID-19 patients change over time, and these can possibly predict or reflect the severity of disease. More, they may present targets for treatment.
New research shows that selective serotonin reuptake inhibitors (SSRIs), a group of drugs commonly used to treat depression, may double the risk of gastrointestinal bleeding, according to researchers from Wake Forest University School of Medicine and colleagues.
› Verified 9 days ago